F. Hoffmann-La Roche AG

Switzerland

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2018 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 June 2017 - 31 May 2018

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 June 2017 - 31 May 2018 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

AC FC
114 54.81

Outputs by subject (FC)

Subject AC FC
Chemistry 30 19.37
Life Sciences 83 35.44
Physical Sciences 1 0.02

Highlight of the month

The factors of immunity

© Oliver Helbig/EyeEm/Getty

© Oliver Helbig/EyeEm/Getty

Sex, age, smoking, and genetics affect numbers and types of circulating immune cells, a research consortium has found. 

The group, including researchers from Genentech, counted and assessed the activation state of innate (present in the body) and acquired (produced in response to a foreign substance) immune cells in, and sequenced the genomes of, 1,000 healthy adults. The data was compared with demographic variables. 

They found men had, for example, a larger number of activated natural killer cells than women. And smokers had larger numbers of active T cells than non-smokers. They also detected a gene variation that affects the expression of a receptor on some types of monocytes. The presence of this receptor helps doctors decide whether septic shock patients could benefit from immune-stimulating therapies. The results indicate that genetic makeup should be considered during testing in these patients. 

They also found other genetic variations in innate immune cells that can be linked to autoimmune diseases, which could provide insights into how the conditions develop.

Supported content

  1. Nature Immunology 19, 302–314 (2018). doi: 10.1038/s41590-018-0049-7

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 June 2017 - 31 May 2018

International vs. domestic collaboration by FC

  • 8.15% Domestic
  • 91.85% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (FC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs